 |
Questions? Call 888-624-8373 |
|
|
|
|
Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter.
Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 36
APPENDIX B
SYMPOSIUM AGENDA
Monday, February 25, 2002
8:00 a.m. Registration and Continental breakfast
8:25
Plenary Session
Welcome
George Kenyon, Ph.D, Symposium Committee Chair, University of Michigan, Ann
Arbor, M}
Proteomics at NIGMS: Why is Structural Genomics not the Same as Structural
Proteomics?
Marvin Cassman, Ph.D., Director, National Institute of General Medical Sciences,
Bethesda MD
Post Genomic Studies of Mitochodria
John E. Walker, Ph.D. Director of the Dunn Human Nutrition Unit, Medical Research
Council, Cambndge, UK
Accelerating Drug Discovery by Targeted Proteomics
Scott Patterson, Ph.D.
Rockville, MD
-
Senior Director for Proteomics, Celera Genomics Group,
Large Scale Proteomics in a Clinical and an Industria! Setting
Denis Hochstrasser, M.D., President of Clinical Medicine, University of Geneva; Head
of Clinical Chemistry Laboratory, Geneva University Hospital; founder, Geneva
Bioinformatics, Switzerland.
10:15 Coffee
10.30 Proteomic Strategies in Health an`Disease
Julio Cells, Ph.D. Institute of Cancer Biology and Danish Centre for Human Genome
Research, Danish Cancer Society, Copenhagen, Denmark.
Data Collection in Proteomics, What Data and How Much?
Ruedi Aebersold, Ph.D., Institute for Systems Biology, Seattle, WA
Scaling up Proteomics: Lessons [earnearfrom the Human Genome Project
Francis Collins, Ph.D., Director, National Human Genome Research Institute,
Bethesda, MD
B-]
OCR for page 37
12:15 Lunch
Structural Proteomics:
Genomics/Proteomics
Part of an Integrated Approach to Functional
Cheryl A~rowsmith, Ph.D., Department of Medical Biophysics, University of Toronto,
Canada
Manipulating the Proteome; Studying Protein Pun ction in the Genomic Area
Joshua LaBaer, M.D., Ph.D., Director of the institute of Proteomics at Harvard Medical
School, Boston, MA
Proteomic Tools for Dissecting Cellular Function
Brian Chait, Ph.D., Rockefeller University, New York, NY
2:45 Break
3-5:00 pm Breakout Sessions tI5 minutes prior to session end, each (co) chair will summarize
main points to be presented to all meeting participants]
5:00 Summaries - 5 minutes per breakout session
6-7:30 pm Reception in Great Hall
$~0SIUM BREAK-OUT SESSIONS
1) Computational Methods & Bioinformatics
This session will focus on the interface between computational and biochemical methods for the
prediction and determination of the functions of gene products. Various experimental
methodologies exist for the direct and indirect elucidation of protein function, including structure
determination, expression and interaction profiling, knockout experiments for phenotype
inference, and mutational analyses. We will examine current computational tools designed to
analyze and integrate these disparate types of data into a functional picture of an organism, and
discuss both what is possible today, and what we need for future research and development in
this complex area.
Cochairs: Kimmen Sjolander, Ph.D., University of California - Berkeley
Dagmar Ringe, Ph.D., Brandeis University, Waltham, MA
2) Platform/Emerging Technologies
Interdisciplinary collaboration in computer science, engineering, and the biosciences has
generated rapid advances in new technologies. This session will discuss some of the
B-2
OCR for page 38
technologies for global quantitative analysis of proteins from complex mixtures, and high
throughput analysis of protein interactions. These new technologies include protein chips,
microarrays, 2D gels, image and data analysis systems.
Cochairs: Ruth Van Bogelen, Ph.D., Head of Genomics & Proteomics, Pfizer Global
Research and Development, Ann Arbor, MI
Norman G. Anderson, Ph.D., Chief Scientist, Large Scale Biology, Rockville, MD
3) Protein Separation' ancildentif cation
New uses are being developed for old technologies such as mass spectrometry and gel
electrophoresis. These technologies provide the tools scientists use to identify proteins and
multi-protein complexes. This session will address the use of mass spectrometry and related
techniques to characterize proteins and protein-protein interactions, structure and folding.
Cochairs: Alma Burlingame, Ph.D., University of California-San Francisco
Julio Cells, Ph.D., Institute of Cancer Biology and Danish Centre for Human
Genome Research, Danish Cancer Society, Copenhagen, Denmark.
Alain Van Dorsselaer, Ph.D., Pasteur University, Strasbourg, France
4) Protein Structure and Function
With the goal of creating an atomic description of each and every constituent of the cell,
worldwide, large-scale structural initiatives are beginning to deliver what, over the next decade,
will be an enormous wave of structural information to the shores of the biological community.
Achieving this goal requires that many new and formidable challenges must be met. While the
structural initiatives are underway, the functional/enzymological programs that will articulate the
functions of these structures are, as yet, in the concept stage, and have recently been explored in
workshops at the NIH/NIGMS. We invite you to help define the important issues that genomic-
scale science has created for the structural and functional communities.
Cochairs: Greg Petsko, Ph.D., Brandeis University, Waltham, MA
Thomas Leyh, Ph.D., The Albert Einstein College of Medicine, New York, NY
5) Metabolic Pathways arid Post - Translationa! Modif cations
Proteomics research presents a much more elusive task than the mapping of the human genome.
Protein modification during protein translation and various metabolic processes, creates a
challenge for defining the mandate of proteomics research. This session will address how
scientists might proceed in annotating proteins, while considering how protein modification and
the metabolic products will affect function and proteomics research.
Cochairs: Edward Dennis, Ph.D., University of California, San Diego
Eugene Bruce, Ph.D., Division of Integrative Biology and Neuroscience
National Science Foundation, Arlington, VA
6) Implementation: Necessary Policy and Infrastructure Conditions for Collaboration'
B-3
at,
OCR for page 39
This session will address the unique/critical needs of proteomics research with respect to
collaboration including education, funding, international cooperation, data sharing policies, and
informatics infrastructure (e.g. software standards, scientific portals, colIaboratories,
computing gnds).
Cochairs: Jim Myers, Ph.D., Computational Science and Mathematics Department, Pacific
Northwest National Laboratory, RichIand, WA
Richard W. Morris, Ph.D., Division of Allergy, Immunology & Transplantation,
National Institute of Allergy and Infectious Disease, NTH, Bethesda, MD
7) Clinica!Aspects
Proteomics research promises to help fundamentally change the practice of medicine in the 2Ist
century. This session will focus on how clinical proteomics research can be used to define new
molecular markers for risk assessment and disease diagnosis, and how it can be used with other
molecular profiling techniques to identify new targets for pharmaceutical development. The use
of protein chips in the drug development and clinical settings will also be discussed.
Cochairs: Alan Sachs M.D, University of California Berkeley; Director, Clinical Genomic
Pharmacology, Merck Research Labs, Inc
Denis Hochstrasser, M.D., President of Clinical Medicine, University of Geneva;
Director of the Depa~-l~ent of Pathology and Head of the Central Clinical
Chemistry Laboratory, Geneva University Hospital
B-4
Representative terms from entire chapter:
genome research
Items in cart [4]
